|
Jan 20, 2010
By:
Walter Armstrong
Pharm Exec's 2010 crystal ball reveals an industry in upheaval on many fronts. Is going back to the future the answer?
|
Dec 1, 2009
By:
Walter Armstrong
As the old orthodoxy shatters, pharma must stand firm or leave the field.
|
|
Oct 1, 2009
By:
Walter Armstrong
Novartis CEO Daniel Vasella has built the Swiss firm into the fastest growing pharma in the world, and in the process gained a reputation as an outspoken visionary. But is he really as good as all that?
|
|
Aug 1, 2009
By:
Walter Armstrong
The Belgian drugmaker is pursuing a sale, inking deals, issuing debt, and launching a power drug for Parkinson's—all at once.
|
|
Aug 1, 2009
By:
Walter Armstrong
With the biotech industry reeling from the recession, big drugmakers hold all the cards when it comes to making deals, but picking a winner is still a gamble. Here are 10 to place stakes on.
|
|
Jul 1, 2009
By:
Walter Armstrong
Chris Viehbacher's first fast and furious six months at the top of Sanofi-Aventis have heads spinning...and rolling.
|
Jun 3, 2009
By:
Walter Armstrong
Due to pharma's voluntary moratorium on doling out totefuls of freebies and all the lattes you can swallow, thousands of docs, researchers, and reporters had only their sleep-deprived selves to carry from data dump to data dump at this week?s American Society of Clinical Oncology (ASCO) annual confab in Orlando, Florida.
|
Mar 1, 2009
By:
Walter Armstrong
Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
|
Feb 1, 2009
By:
Walter Armstrong
For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
